242
Participants
Start Date
October 31, 2012
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
Secukinumab (AIN457)
"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)"
Placebo
Novartis Investigative Site, Panorama
Novartis Investigative Site, Bad Doberan
Novartis Investigative Site, Cumberland
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Bergamo
Novartis Investigative Site, North Charleston
Novartis Investigative Site, Hanover
Novartis Investigative Site, Pembroke Pines
Novartis Investigative Site, Miami
Novartis Investigative Site, Zephyrhills
Novartis Investigative Site, Göttingen
Novartis Investigative Site, Verona
Novartis Investigative Site, Jackson
Novartis Investigative Site, Tupelo
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Bologna
Novartis Investigative Site, Zanesville
Novartis Investigative Site, Edina
Novartis Investigative Site, Rapid City
Novartis Investigative Site, St Louis
Novartis Investigative Site, Lees Summit
Novartis Investigative Site, Oklahoma City
Novartis Investigative Site, Oklahoma City
Novartis Investigative Site, Mesquite
Novartis Investigative Site, Benbrook
Novartis Investigative Site, Houston
Novartis Investigative Site, Houston
Novartis Investigative Site, Amarillo
Novartis Investigative Site, Peoria
Novartis Investigative Site, Albuquerque
Novartis Investigative Site, Reno
Novartis Investigative Site, Santa Monica
Novartis Investigative Site, Upland
Novartis Investigative Site, Catania
Novartis Investigative Site, Bogotá
Novartis Investigative Site, Jaipur
Novartis Investigative Site, Pune
Novartis Investigative Site, Secunderabad
Novartis Investigative Site, Nashville
Novartis Investigative Site, Mar del Plata
Novartis Investigative Site, Rosario
Novartis Investigative Site, San Miguel de Tucumán
Novartis Investigative Site, Santiago de Cali
Novartis Investigative Site, Santo Domingo
Novartis Investigative Site, Panama City
Novartis Investigative Site, Salvador
Novartis Investigative Site, Juiz de Fora
Novartis Investigative Site, Curitiba
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Uherské Hradiště
Novartis Investigative Site, Prague
Novartis Investigative Site, Pirna
Novartis Investigative Site, Athens
Novartis Investigative Site, Athens
Novartis Investigative Site, Heraklion
Novartis Investigative Site, Guatemala City
Novartis Investigative Site, Pune
Novartis Investigative Site, New Delhi
Novartis Investigative Site, Roma
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Takasaki
Novartis Investigative Site, Hiroshima
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Miyagi-gun
Novartis Investigative Site, Nagano
Novartis Investigative Site, Sasebo
Novartis Investigative Site, Setouchi
Novartis Investigative Site, Kawachi-Nagano
Novartis Investigative Site, Tokorozawa
Novartis Investigative Site, Hamamatsu
Novartis Investigative Site, Toyama
Novartis Investigative Site, Panama City
Novartis Investigative Site, Lisbon
Novartis Investigative Site, Lisbon
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY